Kane Biotech Completes Enrollment in U.S. Case Series Studies of its revyve庐 Antimicrobial Wound Gel and Spray
Kane Biotech (OTCQB:KNBIF) has successfully completed enrollment for its revyve庐 Antimicrobial Wound Gel and Spray U.S. Case Series Studies, surpassing its target with 28 participants versus the planned 25. The studies, involving wound care and burn specialists in the U.S., focus on the FDA 510(k) cleared revyve Antimicrobial Wound Gel.
The company plans to present the clinical data at various medical meetings throughout 2025 and 2026. According to Interim CEO Dr. Robert Huizinga, there has been encouraging interest from both clinicians and patients, with revyve products showing potential to significantly improve outcomes for patients with challenging wounds and burns.
Kane Biotech (OTCQB:KNBIF) ha completato con successo l'arruolamento per gli studi di case series statunitensi sul gel e lo spray antimicrobici revyve庐, superando l'obiettivo con 28 partecipanti rispetto ai 25 previsti. Gli studi, condotti con specialisti in cura delle ferite e delle ustioni negli Stati Uniti, si concentrano sul gel antimicrobico revyve, approvato dalla FDA tramite la procedura 510(k).
L'azienda intende presentare i dati clinici in diversi congressi medici durante il 2025 e il 2026. Secondo l'Amministratore Delegato ad interim, il Dr. Robert Huizinga, c'猫 stato un interesse incoraggiante da parte di clinici e pazienti: i prodotti revyve potrebbero migliorare significativamente gli esiti nei pazienti con ferite e ustioni complesse.
Kane Biotech (OTCQB:KNBIF) ha finalizado con 茅xito la incorporaci贸n de participantes en sus estudios de series de casos en EE. UU. sobre el gel y el spray antimicrobianos revyve庐, superando la meta con 28 participantes frente a los 25 previstos. Los estudios, realizados con especialistas en cuidados de heridas y quemaduras en EE. UU., se centran en el gel antimicrobiano revyve aprobado por la FDA mediante 510(k).
La compa帽铆a planea presentar los datos cl铆nicos en varias reuniones m茅dicas a lo largo de 2025 y 2026. Seg煤n el CEO interino, el Dr. Robert Huizinga, ha habido un inter茅s alentador por parte de cl铆nicos y pacientes; los productos revyve muestran potencial para mejorar significativamente los resultados en pacientes con heridas y quemaduras dif铆ciles.
Kane Biotech (OTCQB:KNBIF)電� 氙戈淡鞐愳劀 歆勴枆頃� revyve庐 頃靸濍 靸侅矘 瓴� 氚� 鞀ろ攧霠堨澊 靷 鞁滊Μ歃� 鞐瓣惮鞚� 霌彪鞚� 靹标车鞝侅溂搿� 鞕勲頄堨溂氅�, 瓿勴殟霅� 25氇呺炒雼� 毵庫潃 28氇呾潣 彀戈皜鞛�鞚� 頇曤炒頄堨姷雼堧嫟. 氙戈淡鞚� 靸侅矘 氚� 頇旍儊 旃橂 鞝勲臧�霌り臣 頃粯頃� 鞚� 鞐瓣惮霌れ潃 FDA 510(k) 項堦皜毳� 氚涭潃 revyve 頃靸濍 靸侅矘 瓴旍棎 欷戩爯鞚� 霊愱碃 鞛堨姷雼堧嫟.
須岇偓電� 鞛勳儊 雿办澊韯半ゼ 2025雲� 氚� 2026雲� 霃欖晥 雼れ枒頃� 鞚橅暀 頃欗殞鞐愳劀 氚滍憸頃� 瓿勴殟鞛呺媹雼�. 鞛勳嫓 CEO鞚� 搿滊矂韸� 頃橃澊歆曥晞 氚曥偓鞐� 霐半ゴ氅� 鞛勳儊鞚橃檧 頇橃瀽霌� 氇憪搿滊秬韯� 瓿犽鞝侅澑 甏�鞁澊 鞛堨棃鞙茧┌, revyve 鞝滍拡鞚� 雮滌箻靹� 靸侅矘 氚� 頇旍儊 頇橃瀽鞚� 旃橂 瓴瓣臣毳� 韥矊 臧滌劆頃� 臧�電レ劚鞚� 鞛堧嫟瓿� 頃╇媹雼�.
Kane Biotech (OTCQB:KNBIF) a termin茅 avec succ猫s le recrutement pour ses 茅tudes de s茅ries de cas am茅ricaines sur le gel et le spray antimicrobiens revyve庐, d茅passant l'objectif avec 28 participants contre 25 pr茅vus. Les 茅tudes, men茅es avec des sp茅cialistes des plaies et des br没lures aux 脡tats-Unis, portent sur le gel antimicrobien revyve approuv茅 par la FDA via la proc茅dure 510(k).
La soci茅t茅 pr茅voit de pr茅senter les donn茅es cliniques lors de diff茅rentes r茅unions m茅dicales en 2025 et 2026. Selon le PDG par int茅rim, le Dr Robert Huizinga, l'int茅r锚t des cliniciens et des patients est encourageant : les produits revyve pourraient consid茅rablement am茅liorer les r茅sultats des patients souffrant de plaies et de br没lures difficiles.
Kane Biotech (OTCQB:KNBIF) hat die Rekrutierung f眉r seine US-Fallserien-Studien zum revyve庐 antimikrobiellen Wundgel und -spray erfolgreich abgeschlossen und mit 28 Teilnehmern das Ziel von 25 眉bertroffen. Die Studien, an denen Wund- und Verbrennungsspezialisten in den USA beteiligt sind, konzentrieren sich auf das von der FDA per 510(k) zugelassene revyve antimikrobielle Wundgel.
Das Unternehmen plant, die klinischen Daten auf verschiedenen medizinischen Tagungen in den Jahren 2025 und 2026 vorzustellen. Laut Interim-CEO Dr. Robert Huizinga besteht sowohl bei Klinikern als auch bei Patienten ermutigendes Interesse; die revyve-Produkte k枚nnten die Ergebnisse f眉r Patienten mit schwierigen Wunden und Verbrennungen deutlich verbessern.
- Exceeded enrollment target with 28 participants vs planned 25
- FDA 510(k) clearance already obtained for revyve Antimicrobial Wound Gel
- Strong interest from clinicians and patients in the U.S.
- Results from the case series are not yet available
- Data presentation timeline extends into 2026, indicating a lengthy evaluation process
WINNIPEG, Manitoba, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (鈥淜ane Biotech鈥� or 鈥淜ane鈥�) today announces that it has enrolled 28 participants in its revyve庐 Antimicrobial Wound Gel and Spray U.S. Case Series Studies, exceeding its 25-participant target.
US FDA 510(k) cleared revyve Antimicrobial Wound Gel
For the clinical series, Kane engaged wound care and burn specialists in the U.S. Data is anticipated to be presented at various medical meetings in 2025 and 2026.
鈥淚nterest from clinicians and patients in the U.S. case series is encouraging,鈥� said Dr. Robert Huizinga, Interim CEO. 鈥渞evyve products can meaningfully improve outcomes for those suffering from challenging wounds and burns.鈥�
About Kane Biotech Inc. (TSX-V: KNE)
Kane Biotech is developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds which results in serious clinical outcomes and significant cost. revyve庐 addresses both biofilms and wound bacteria. Its revyve庐 Antimicrobial Wound Gel and revyve庐 Antimicrobial Wound Gel Spray are US FDA 510(k) cleared. To learn more about revyve, visit or .
Join Kane鈥檚 Distribution List & Social Media:
To stay informed on the latest developments, sign-up for the Company鈥檚 email distribution list听.
Follow Kane
Website:
LinkedIn:
For more information:
| Dr. Robert Huizinga | 听 | Ray Dupuis |
| Interim CEO | 听 | Chief Financial Officer |
| Kane Biotech Inc. | 听 | Kane Biotech Inc. |
| [email protected] | 听 | [email protected] |
| (780) 970-1100 | 听 | (204) 298-2200 |
| 听 | 听 | 听 |
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities听law.听These statements reflect management鈥檚 current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company鈥檚: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at听www.sedar+.ca. The Company cautions that the foregoing list of factors that may affect future results is not听exhaustive.
A photo accompanying this announcement is available at
FAQ
How many participants did Kane Biotech enroll in its revyve wound treatment case series?
What is the regulatory status of Kane Biotech's revyve Antimicrobial Wound Gel?
When will Kane Biotech (KNBIF) present the results of its revyve case series?
What conditions does Kane Biotech's revyve product target?
Who is leading Kane Biotech's revyve clinical studies?
